BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35551629)

  • 21. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
    Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action.
    Russell LM; Hultz M; Searson PC
    J Control Release; 2018 Jan; 269():171-176. PubMed ID: 29122661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of
    Li X; Chen C; Ding N; Zhang T; Zheng P; Yang M
    Front Pharmacol; 2022; 13():1073535. PubMed ID: 36588682
    [No Abstract]   [Full Text] [Related]  

  • 24. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.
    Huang W; Czuba LC; Isoherranen N
    J Pharmacol Exp Ther; 2020 Jun; 373(3):488-501. PubMed ID: 32198137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.
    Soundararajan A; Bao A; Phillips WT; Perez R; Goins BA
    Nucl Med Biol; 2009 Jul; 36(5):515-24. PubMed ID: 19520292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
    Ren C; Wang Y; Zhang M; Kong D; Ning C; Cheng Y; Bian Y; Sun M; Su S; Wang Y; Zhang Y; Lu Y; Li N; Zhao D; Chen X
    Pharm Res; 2021 Nov; 38(11):1847-1862. PubMed ID: 34773182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery.
    Talkington AM; Wessler T; Lai SK; Cao Y; Forest MG
    Bull Math Biol; 2021 Nov; 83(12):123. PubMed ID: 34751832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
    Mayumi K; Ohnishi S; Hasegawa H
    J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution.
    Zazo H; Colino CI; Gutiérrez-Millán C; Cordero AA; Bartneck M; Lanao JM
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictions of tissue concentrations of myclobutanil, oxyfluorfen, and pronamide in rat and human after oral exposures via GastroPlus
    Zhang F; Erskine TC; McClymont EL; Moore LM; LeBaron MJ; McNett D; Marty SS
    SAR QSAR Environ Res; 2024 Apr; 35(4):285-307. PubMed ID: 38588502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model].
    Yu MM; Gao ZW; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2014 Dec; 49(12):1684-8. PubMed ID: 25920197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice.
    Lin Z; Monteiro-Riviere NA; Riviere JE
    Nanotoxicology; 2016; 10(2):162-72. PubMed ID: 25961857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel physiologically based pharmacokinetic model of rectal absorption, evaluated and verified using clinical data on 10 rectally administered drugs.
    Dancik Y; Mittapelly N; Puttrevu SK; Polak S
    Int J Pharm; 2023 Aug; 643():123273. PubMed ID: 37507097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
    Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies.
    Bao A; Goins B; Klipper R; Negrete G; Phillips WT
    J Pharmacol Exp Ther; 2004 Feb; 308(2):419-25. PubMed ID: 14610219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
    Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
    Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.
    Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H
    Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.